Veru (STU:FMW0) ROCE %: -74.40% (As of Mar. 2026)


STU:FMW0 Veru Inc STU:FMW0
28 GF Score
Price €3.11
! 2 Warning Signs
View Full Analysis

What is Veru ROCE %?

Veru STU:FMW0 28 ROCE % is -74.40% as of Mar. 2026. GuruFocus rates STU:FMW0 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Veru's annualized ROCE % for the quarter that ended in Mar. 2026 was -74.40%.

Veru  (STU:FMW0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Veru ROCE % Related Terms

Veru ROCE % Historical Data

* Premium members only.

The historical data trend for Veru's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru ROCE % Chart

Veru Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.16 -68.10 -132.33 -91.14 -96.82

Veru Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -118.11 -129.76 -138.57 -69.49 -74.40
STU:FMW0
28GF Score
Veru Inc STU:FMW0
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veru ROCE % Calculation

Veru's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=-30.272/( ( (54.438 - 10.693) + (25.42 - 6.633) )/ 2 )
=-30.272/( (43.745+18.787)/ 2 )
=-30.272/31.266
=-96.82 %

Veru's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-24.976/( ( (40.622 - 6.087) + (37.267 - 4.661) )/ 2 )
=-24.976/( ( 34.535 + 32.606 )/ 2 )
=-24.976/33.5705
=-74.40 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -74.40% mean?
Veru (STU:FMW0) has a ROCE % of -74.40% as of Mar. 2026.
Is Veru's ROCE % too high?
Veru's current ROCE % is -74.40%. Overall, Veru has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Veru's ROCE % compare to AURX and PDSB?
Veru's ROCE % of -74.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Veru's current ROCE % is -74.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veru stock overvalued right now?
Veru (STU:FMW0) has a current ROCE % of -74.40%. The current ROCE % is -74.40%. Veru's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Veru (STU:FMW0), the current ROCE % is -74.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veru Business Description

Other Exchanges VERU:USA
Address 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
28GF Score

Get the complete analysis for STU:FMW0

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.11
Price